CRISPR Therapeutics (CRSP) Balance Sheet Annual - Discounting Cash Flows
CRISPR Therapeutics AG
CRSP (NASDAQ)

* (except for per share items) of USD
Period Ending: 2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
2017
12-31
2016
12-31
2015
12-31
2014
12-31
Report Filing: 2024-02-21 2023-02-21 2022-02-15 2021-02-16 2020-02-12 2019-02-25 2018-03-08 2017-03-10 2015-12-31 2014-12-31
Total Current Assets
Cash and Short Term Investments
Cash & Equivalents
Short Term Investments
Receivables
Inventory
Other Current Assets
Total Assets
Total Non-Current Assets
Property, Plant and Equipment
Goodwill and Intangible Assets
Goodwill
Intangible Assets
Long Term Investments
Deferred Tax Assets
Other Long Term Assets
Total Current Liabilities
Accounts Payable
Notes Payable/Short Term Debt
Tax Payables
Deferred Revenue
Other Current Liabilities
Total Liabilities
Total Non-Current Liabilities
Total Long Term Debt
Deferred Tax Liabilities Non-Current
Deferred Revenue Non-Current
Capital Lease Obligations
Other Long Term Liabilities
Total Equity
Non-Controlling Interest
Total Stockholders' Equity
Retained Earnings
Accumulated Other Earnings
Common Stock
Preferred Stock
Additional Paid in Capital
Total Liabilities & Total Equity
Total Liabilities & Shareholders' Equity
Total Investments
Total Debt
Net Debt
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us